About Nanobiotix S.A. American Depositary Shares
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
Market Cap
$0.16B
Employees
110
Listed Since
December 11, 2020
Website
www.nanobiotix.comCIK
0001760854
No content available for this security